Hong Kong (HSI) Drug Retail Industry Analysis
UpdatedMay 19, 2024
DataAggregated Company Financials
Companies5
- 7D3.3%
- 3M-1.5%
- 1Y-39.6%
- YTDn/a
Over the last 7 days, the Drug Retail industry has risen 5.6%, driven by gains from every company within the industry. However, the industry is down 41% over the past year. Looking forward, earnings are forecast to grow by 22% annually.
Industry Valuation and Performance
Has the Hong Kong Drug Retail Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 19 May 2024 | HK$170.5b | HK$103.7b | HK$2.3b | 50.7x | 73.3x | 1.6x |
| Tue, 16 Apr 2024 | HK$138.7b | HK$103.8b | HK$2.3b | 41.5x | 59.5x | 1.3x |
| Thu, 14 Mar 2024 | HK$174.8b | HK$105.1b | -HK$1,456,509,455.21 | 58x | -120x | 1.7x |
| Sat, 10 Feb 2024 | HK$163.3b | HK$105.1b | -HK$1,482,861,775.89 | 52.1x | -110.1x | 1.6x |
| Mon, 08 Jan 2024 | HK$188.5b | HK$105.8b | -HK$1,465,349,501.00 | 58.4x | -128.6x | 1.8x |
| Wed, 06 Dec 2023 | HK$205.2b | HK$105.8b | -HK$1,465,836,294.00 | 64.4x | -140x | 1.9x |
| Fri, 03 Nov 2023 | HK$205.5b | HK$101.8b | -HK$1,735,605,163.00 | 86.2x | -118.4x | 2x |
| Sun, 01 Oct 2023 | HK$230.3b | HK$102.5b | -HK$1,677,457,985.00 | 101.5x | -137.3x | 2.2x |
| Tue, 29 Aug 2023 | HK$236.0b | HK$102.2b | -HK$1,953,899,230.00 | 75.3x | -120.8x | 2.3x |
| Thu, 27 Jul 2023 | HK$282.0b | HK$96.5b | -HK$4,187,878,686.00 | 125.9x | -67.3x | 2.9x |
| Sat, 24 Jun 2023 | HK$250.0b | HK$96.5b | -HK$4,184,749,752.00 | 103.9x | -59.7x | 2.6x |
| Mon, 22 May 2023 | HK$269.6b | HK$93.7b | -HK$4,797,730,813.00 | 408.6x | -56.2x | 2.9x |
| Wed, 19 Apr 2023 | HK$316.8b | HK$96.0b | -HK$4,914,442,509.00 | 485.8x | -64.5x | 3.3x |
Price to Earnings Ratio
-196.4x
Current Industry PE
- Investors are pessimistic on the Hong Kong Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 72.6x which is lower than its 3-year average PE of 142x.
- The 3-year average PS ratio of 2.3x is higher than the industry's current PS ratio of 1.6x.
Past Earnings Growth
- Total earnings for the Drug Retail industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 4.5% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Comparison
How does Hong Kong Drug Retail compare with similar industries?
| HK Market | 2.56% | |
| Consumer Staples | 1.10% | |
| Food and Staples Retail | 3.15% | |
| Drug Retail | 3.35% | |
| Big Box Super Stores | 5.46% | |
| Food Retail | 2.50% | |
| Food Distributors | -0.84% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6618 JD Health International | HK$30.30 | 2.7% +HK$2.6b | -38.5% | PE41.8x | |
| 241 Alibaba Health Information Technology | HK$3.27 | 3.2% +HK$1.6b | -30.1% | PE59.6x | |
| 9886 Dingdang Health Technology Group | HK$1.85 | 42.3% +HK$737.8m | -20.6% | PS0.5x | |
| 1833 Ping An Healthcare and Technology | HK$12.68 | 4.8% +HK$648.9m | -29.8% | PS2.8x |